Pharmacokinetics and safety of inhaled oxytocin compared with intramuscular oxytocin in women in the third stage of labour: A randomized open‐label study
Open Access
- 31 August 2023
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (12) , 3681-3689
Abstract
Aims: To compare pharmacokinetics (PK) and safety of heat‐stable inhaled (IH) oxytocin with intramuscular (IM) oxytocin in women in third stage of labour (TSL), the primary endpoint being PK profiles of oxytocin IH and secondary endpoint of safety.Methods: A phase 1, randomized, cross‐over study was undertaken in 2 UK and 1 Australian centres. Subjects were recruited into 2 groups: Group 1, women in TSL; Group 2, nonpregnant women of childbearing potential (Cohort A, combined oral contraception; Cohort B, nonhormonal contraception). Participants were randomized 1:1 to: Group 1, oxytocin 10 IU (17 μg) IM or oxytocin 240 IU (400 μg) IH immediately after delivery; Group 2, oxytocin 5 IU (8.5 μg) intravenously and oxytocin 240 IU (400 μg) IH at 2 separate dosing sessions.Results: Participants were recruited between 23 November 2016 to 4 March 2019. In Group 1, 17 participants were randomized; received either IH (n = 9) or IM (n = 8) oxytocin. After IH and IM administration, most plasma oxytocin concentrations were below quantification limits (2 pg/mL). In Group 2 (n = 14), oxytocin IH concentrations remained quantifiable ≤3 h postdose. Adverse events were reported in both groups, with no deaths reported: Group 1, IH n = 3 (33%) and IM n = 2 (25%); Group 2, n = 14 (100%).Conclusion: Safety profiles of oxytocin IH and IM were similar. However, PK profiles could not be established for oxytocin IH or IM in women in TSL, despite using a highly sensitive and specific assay.Keywords
Funding Information
- GlaxoSmithKline (NCT02999100)
This publication has 11 references indexed in Scilit:
- Quality of medicines for life-threatening pregnancy complications in low- and middle-income countries: A systematic reviewPLOS ONE, 2020
- Knowledge, perception and practice towards oxytocin stability and quality: A qualitative study of stakeholders in three resource-limited countriesPLOS ONE, 2018
- Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 StudyEBioMedicine, 2017
- Effect of different doses of oxytocin on cardiac electrophysiology and arrhythmias induced by ischemiaJournal of Advanced Pharmaceutical Technology & Research, 2017
- Barriers and facilitators to the quality use of essential medicines for maternal health in low–resource countries: An Ishikawa frameworkJournal of Global Health, 2015
- Treatment for primary postpartum haemorrhageCochrane Database of Systematic Reviews, 2014
- Hemodynamic effects of continuous intravenous injection and bolus plus continuous intravenous injection of oxytocin in cesarean sectionKorean Journal of Anesthesiology, 2011
- Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean sectionBritish Journal of Anaesthesia, 2006
- Effect of human pregnancy on metabolic clearance rate of oxytocinAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1990
- Elevated Plasma Levels Of Oxytocin In Women Taking Low‐Dose Oral Contraceptives: Identification Of The Plasma Oxytocin With High Performance Liquid ChromatographyActa Obstetricia et Gynecologica Scandinavica, 1989